Targeting CD40/CD40L signaling has also been investigated in the context of CLL, with monoclonal antibody to CD40 Selicrelumab showing promising results through the sensitization of CD20 monoclonal antibodies such as Rituximab and Obinutuzumab (114, 115). Here, CD40 is linked to B-cell chronic lymphocytic leukemia.